Analysis of High-Dose-Rate Brachytherapy Outcomes in Prostate Cancer Patients Aged 75 and Older - Takeaways - MDSpire

Analysis of High-Dose-Rate Brachytherapy Outcomes in Prostate Cancer Patients Aged 75 and Older

  • By

  • Keiji Matsuda

  • Takeshi Ogata

  • Nobuhiko Kamitani

  • Kenta Watanabe

  • Ryoji Tokiya

  • Takafumi Hayashi

  • Yoshiyuki Miyaji

  • Kazumasa Komura

  • Tsutomu Tamada

  • Kuniaki Katsui

  • January 7, 2026

  • 0 min

Share

  • 1

    Prostate cancer is the second most common cancer in men, with a rising incidence among older individuals, particularly those aged 70-74.

  • 2

    High-dose-rate brachytherapy (HDR-BT) combined with external beam radiation therapy (EBRT) improves disease-free survival in localized prostate cancer.

  • 3

    Older patients, defined as those aged 75 and older, often have comorbidities that complicate treatment decisions for prostate cancer.

  • 4

    The study aims to evaluate HDR-BT outcomes in older prostate cancer patients compared to younger patients, addressing a gap in existing literature.

  • 5

    Statistical methods, including propensity score matching, were employed to minimize bias in comparing treatment outcomes between age groups.

Original Source(s)

Analysis of High-Dose-Rate Brachytherapy Outcomes in Prostate Cancer Patients Aged 75 and Older

  • by Keiji Matsuda, Takeshi Ogata, Nobuhiko Kamitani, Kenta Watanabe, Ryoji Tokiya, Takafumi Hayashi, Yoshiyuki Miyaji, Kazumasa Komura, Tsutomu Tamada, Kuniaki Katsui

  • January 7, 2026

Related Content

VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation

Lifestyle and Surveillance Adherence After Childhood Cancer—When Financial Hardship Shapes Survivorship

The role of NAD+ metabolic reprogramming in colorectal cancer chemoresistance: mechanistic insights, clinical translation challenges and opportunities